Podcasts about Mayo Clinic Arizona

We are kicking off the new year and a new season with a great guest! Dr. Kristen Steenerson, MD brings her expertise to the conversation with a deeper dive into Vestibular Migraine and Persistent Postural Perceptual Dizziness. Whether you're a patient or a clinician, you surely don't want to skip this episode! Kristen K. Steenerson, MD is a board-certified neurologist with fellowship training in vestibular neurology. She graduated cum laude from Claremont McKenna College, received her MD from the University of Utah, completed neurology residency at Mayo Clinic Arizona, and fellowship at Barrow Neurological Institute. She directs the Vestibular Balance Disorders Program of the Stanford Balance Center. She has joint appointments in the departments of Otolaryngology--Head and Neck Surgery and Neurology & Neurological Sciences at Stanford. Her clinical interests include vestibular migraine, persistent postural-perceptual dizziness, benign paroxysmal positional vertigo, Ménière's disease, and international neurology. Episode Resources - Central and peripheral vestibular disorders overview (and how much they overlap!): https://www.nature.com/articles/nrneurol.2017.58 - CGRP position paper: https://pubmed.ncbi.nlm.nih.gov/38466028/ - VMPATHI survey:https://redcap.ucsf.edu/surveys/?s=CY893NJHCM - VMPATHI paper: https://pubmed.ncbi.nlm.nih.gov/32176141/ - Comprehensive analysis of VM treatments: https://pubmed.ncbi.nlm.nih.gov/35859353/ - Migraine influences tinnitus and hearing loss: https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/ohn.201?casa_token=pfzZz62NjqcAAAAA:u0enZoqzF6n8D1_o_7G4HyTY5qpjFd0cDutwNpFtigKXd7xo4Zo65Cuzy4qZWjHDeuMICp0RYuKrGQ - Cognitive failures improve when migraine improves: https://pubmed.ncbi.nlm.nih.gov/37525385/ - Treat MdDS as migraine: https://pmc.ncbi.nlm.nih.gov/articles/PMC5823515/ - Magazine article: https://www.bustle.com/p/what-actually-happens-in-your-brain-when-you-have-a-migraine-according-to-experts-16823975 Hosted by Dr. Abbie Ross, PT, NCS, and Dr. Danielle Tolman, PT For Episode Recommendations or Requests, email us info@balancingactrehab.com Where to find us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://link.me/balancingactrehab⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.BalancingActRehab.com⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠Facebook: @BalancingActRehab Instagram: @BalancingActRehab Twitter: @DizzyDoctors TikTok: @BalancingActRehab

This podcast discussed the topic of "Improving consistency and reducing human bias for physicians' target contouring using AI auto-segmentation." Experts joining the discussion include Steve Jiang, PhD, Professor and Vice Chair in Department of Radiation Oncology at University of Texas Southwestern and Director of Medical Artificial Intelligence and Automation Lab, Nathan Yu, MD, Assistant Professor in Department of Radiation Oncology, Mayo Clinic Arizona, and Yi Rong, PhD, Professor and Lead photon physicist in Department of Radiation Oncology at Mayo Clinic Arizona. This podcast focused on the utility of AI in automatic segmentation of medical imaging and the challenges related to physician variability in clinical practice. We discussed various strategies for addressing these challenges, including developing physician-style aware AI models and balancing standardization with personalization in AI tool development and deployment. The emphasis is on the feasibility and clinical utility of using AI to improve the accuracy and efficiency of medical image segmentation while respecting the art and personalization inherent in clinical medicine.

This podcast discussed the topic of "Improving consistency and reducing human bias for physicians' target contouring using AI auto-segmentation." Experts joining the discussion include Steve Jiang, PhD, Professor and Vice Chair in Department of Radiation Oncology at University of Texas Southwestern and Director of Medical Artificial Intelligence and Automation Lab, Nathan Yu, MD, Assistant Professor in Department of Radiation Oncology, Mayo Clinic Arizona, and Yi Rong, PhD, Professor and Lead photon physicist in Department of Radiation Oncology at Mayo Clinic Arizona. This podcast focused on the utility of AI in automatic segmentation of medical imaging and the challenges related to physician variability in clinical practice. We discussed various strategies for addressing these challenges, including developing physician-style aware AI models and balancing standardization with personalization in AI tool development and deployment. The emphasis is on the feasibility and clinical utility of using AI to improve the accuracy and efficiency of medical image segmentation while respecting the art and personalization inherent in clinical medicine.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this special episode, we've compiled some of the most compelling conversations from Mind Moments podcast episodes throughout 2024. These discussions spotlight groundbreaking research and advancements in neurology that are propelling the field forward. The NeurologyLive team also explored the impact of several newly FDA-approved therapies, offering clinicians valuable insights into what these treatments mean for patient care and their practical use in the clinic. Featured in this week's episode, in order of appearance, are: Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, who gave an overview on the new 2024 McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Check out the full episode here: https://www.neurologylive.com/view/episode-125-understanding-major-changes-new-mcdonald-criteria-multiple-sclerosis Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, on the changing and exciting advances in Alzheimer disease therapeutics, as well as the discontinuation of aducanumab, the first approved antiamyloid therapy. Check out the full episode here: https://www.neurologylive.com/view/episode-113-lessons-learned-alzheimer-drug-development Andy Berkowski, MD, PhD, vice chair of the American Academy of Sleep Medicine's Practice Guidelines Task Force, discusses the newly revised guidelines for restless legs syndrome, including the latest updates in literature and changes to clinical care. Check out the full episode here: https://www.neurologylive.com/view/episode-129-implications-2024-aasm-guidelines-restless-legs-syndrome Sameea Husain-Wilson, DO, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease.Check out the full episode here: https://www.neurologylive.com/view/episode-119-utilizing-the-syn-one-test-to-diagnose-parkinson-disease Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke at the 2024 American Epilepsy Society Annual Meeting on cell therapy approaches for epilepsy, the challenges the clinical community faces, and the outlook for the future. Check out the full episode here: https://www.neurologylive.com/view/episode-130-promise-behind-cell-therapy-approaches-epilepsy Lawrence Robinson, MD, a senior scientist at Sunnybrook Research Institute, gives insight on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners, and the major differences in how this generation of medical students learn relative to previous ones. Check out the full episode here: https://www.neurologylive.com/view/episode-127-adapting-neuromuscular-electrodiagnostic-medicine-education-modern-learners Want more Mind Moments episodes? Click here for all of NeurologyLive®'s podcast episodes. Episode Breakdown: 1:05 – Ontaneda on the incorporation of new biomarkers into the 2024 McDonald Criteria for multiple sclerosis. 7:35 – Kremer on the lessons learned from drug development, including antiamyloid treatments, and initial reaction to the discontinuation of aducanumab for AD.  10:30 – Berkowski on the outlook of treating and preventing restless legs syndrome going forward using the newly updated American Academy of Sleep Medicine treatment guidelines.  13:10 – Husain-Wilson on the function of the Syn-One test for Parkinson disease, its applicability, and how it may distinguish patients with PD from other synucleinopathies. 18:40 – Parker on the promise and thought process behind stem cell approaches for drug-resistant epilepsy, including the different types of cell methods being tested.  21:45 – Robinson on the distinct differences in learning styles based on generation, the importance of adaptive teaching, and the new approaches educators in neuromuscular and electrodiagnostic medicine can take.  Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

CardioNerds (Dr. Dan Ambinder and guest host, Dr. Pooja Prasad) join Dr. Donny Mattia from Phoenix Children's pediatric cardiology fellowship, Dr. Sri Nayak from the Mayo Clinic – Arizona adult cardiology fellowship, and Dr. Harrison VanDolah from the University of Arizona College of Medicine - Phoenix Med/Peds program for a sunrise hike of Piestewa Peak, followed by some coffee at Berdena's in Old Town Scottsdale (before the bachelorette parties arrive), then finally a stroll through the Phoenix Desert Botanical Gardens to discuss a thought-provoking case series full of clinical cardiology pearls. Expert commentary is provided by Dr. Tabitha Moe. Episode audio was edited by Dan Ambinder. They discuss the following case: Cardiology is consulted by the OB team for a 27-year-old female G1, now P1, who has just delivered a healthy baby boy at 34 weeks gestation after going into premature labor. She is experiencing shortness of breath and is found to have a significant past cardiac history, including atrial fibrillation and preexcitation, now with a pacemaker and intracardiac defibrillator. We review the differential diagnosis for peripartum cardiomyopathy (PPCM) and then combine findings from her infant son, who is seen by our pediatric cardiology colleagues and is found to have severe hypertrophic cardiomyopathy (HCM). Genetic testing for both ultimately reveals a LAMP2 mutation consistent with Danon Disease. The case discussion focuses on the differential diagnosis for PPCM, HCM, pearls on Danon Disease and other HCM “phenocopies,” and the importance of good history. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media Pearls Peripartum cardiomyopathy is a diagnosis of exclusion – we must exclude other possible etiologies of heart failure! Be on the lookout for features of non-sarcomeric HCM – as Dr. Michelle Kittleson said in Episode 166, “LVH plus” states. HCM with preexcitation, heart block, strong family history, or extracardiac symptoms such as peripheral neuropathy, myopathy, or cognitive impairment should be evaluated for infiltrative/inherited cardiomyopathies! As an X-linked dominant disorder, Danon disease will present differently in males vs females, with males having much more severe and earlier onset disease with extracardiac features. Making the diagnosis for genetic disorders such as Danon disease is important for getting the rest of family members tested as well as the opportunity for specialized treatments such as gene therapy Up to 5% of Danon disease cases may be due to copy number variants, which may be missed in genetic testing that does not do targeted deletion/duplication analysis!). Notes What is the differential diagnosis for peripartum cardiomyopathy? Peripartum cardiomyopathy is a diagnosis of exclusion – we must exclude other possible etiologies of heart failure! First, ensure that you are not missing an acute life-threatening etiology of acute decompensated heart failure – pulmonary embolism, amniotic fluid embolism, ACS, and SCAD should all be ruled out. Second, a careful history can identify underlying heart disease or risk factors for the development of heart failure, such as substance use, high-risk behaviors that put one at risk for HIV infection, and family history that suggests an inheritable cardiomyopathy. Lastly, a careful review of echocardiographic imaging may also identify underlying etiologies that warrant a change in management. Diagnosis of peripartum cardiomyopathy is important to consider as within 7 days of onset, patients may be eligible for treatment with bromocriptine – consider referring ...

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke about the emerging commotion around cell therapies as a way to treat patients with epilepsy. The discussion, which took place at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California, covers the thought process behind this approach and why it may hold greater advantages over other traditional surgeries that result in detrimental cognitive effects. Parker, director of the Device-Based Neuroelectronics Lab, spoke on the different types of cell therapies currently in development, the limitations and challenges associated with these medications, and the need to create innovative trials to appropriately test them. Furthermore, Parker spoke on the therapeutic pipeline of cell therapies for epilepsy, including his experience leading a study site for a first-in-human trial of an investigational agent NRTX-1001, a product derived from human pluripotent stem cells. Looking for more epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:00 – Idea behind cell therapy to treat epilepsy 4:05 – Current state of stem cell therapies for neurological disorders, focusing on Parkinson disease, stroke, and epilepsy 8:05 – NTE001 study of NRTX-1001, an investigational human embryonic stem cell product 11:45 – Neurology News Minute 13:50 – Unanswered questions and safety concerns with cell therapies; challenges with clinical trial design and the need for more innovative trials 17:35 – Misconceptions or gaps in understanding about cell therapies for epilepsy 20:05 – Unique challenges and potential of stem cell therapies for epilepsy, particularly in younger patients; patient motivation and hope The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Anavex Submits Marketing Authorization Application for Blarcamesine in Alzheimer Disease in the EU Testing Begins for RELIEV-CM2 Study of ShiraTronics Neuromodulation Device in Chronic Migraine STK-001 Gains FDA Breakthrough Designation as Potential Disease-Modifying Treatment for Dravet Syndrome Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Primary ovarian insufficiency (POI) sends about 4% of women into premature menopause before the age of 40. Yet, the condition is little understood and for those experiencing it, incredibly isolating. This week we talk about the struggles women with premature menopause face with athlete and entrepreneur Christy Napolitano Wernau, who experienced premature menopause at age 38. We also talk with her doctor, national expert and leader in menopause, Jewel Kling, MD, MPH, about the unique care women with premature menopause require, especially when it comes to menopausal hormone therapy.Christy Napolitano Wernau is an accomplished entrepreneur and advocate for women's health. With 27 years of experience at McDonald's, she became a franchise owner, managing multiple restaurants and teams. She serves as a board member for Ronald McDonald House Charities (RMHC), contributing to impactful community work. Diagnosed with premature ovarian failure and experiencing menopause at 38, she is passionate about raising awareness and building a supportive community for women navigating non-traditional menopause. A dedicated wife, fitness enthusiast, and mother, she balances her personal and professional life with a love for travel and wellness. Currently, she's pursuing a degree in Organizational Leadership with a minor in sociology, and she's an advocate for self-growth and resilience. Jewel Kling, MD, MPH, is a Professor of Medicine, Chair of the Division of Women's Health Internal Medicine, Assistant Director of the Mayo Clinic Women's Health Center and Dean of the Mayo Clinic Alix School of Medicine AZ campus at the Mayo Clinic in Scottsdale, Arizona. Her clinical and research interests are in menopause, sexual health, LGBT care, education, as well as efforts to expand the discipline of Sex and Gender specific medicine. Dr. Kling is recognized as an institutional and national expert and leader in menopause. She is a Menopause Society Certified Practitioner, a fellow and board member of the International Society for the Study of Women's Sexual Health (ISSWSH), and board member of the American Medical Women's Association Sex and Gender Health Collaborative. She is also part of the transgender and intersex specialty clinic committee at Mayo Clinic Arizona and has been a past co-chair of the LGBTI Mayo Employee Resource Group.Resources

This past August, the Mayo Clinic had accomplished what was believed to be impossible… The world's FIRST successful *total* laryngeal transplant on a patient with active cancer! Doctors at Mayo Clinic Arizona completed the procedure on Marty, a 60-year old man with a rare form of laryngeal cancer called chondrosarcoma. A team of 6 physicians […] The post 343 – Total Laryngeal Transplant: Dr. Lott and Jessica Gregor Share the Details Behind This Major Medical Milestone appeared first on Swallow Your Pride Podcast.

In this episode of ASTCT Talks, host Dr. Andrés Gómez De León is joined by Dr. Nandita Khera and Dr. Alexandra Gomez Arteaga to explore the critical issue of disparities and barriers to care in graft-versus-host disease (GVHD). The discussion delves into the factors contributing to unequal access to hematopoietic cell transplantation, such as socioeconomic status, race, and ethnicity, both in the U.S. and globally. The guests highlight initiatives like the ACCESS Initiative by ASTCT and the National Marrow Donor Program, aimed at addressing these disparities through advocacy, awareness, and training for junior faculty. They also discuss the importance of caregiver support, clinical trial accessibility, and the broader impacts of GVHD on patients' lives. Tune in to gain valuable insights into ongoing efforts to promote equitable access to life-saving treatments. About Dr. Nandita Khera Nandita Khera is a Professor of Medicine in the Mayo Clinic College of Medicine and a Consultant in the Division of Hematology/ Oncology at Mayo Clinic Arizona. She treats patients with hematological malignancies and some solid tumors, especially those needing blood and marrow transplant/cell therapy (BMT/CT). Her research focuses on improving the delivery of care to patients with cancer including those undergoing BMT/CT to help them be better prepared for the psychosocial and financial consequences of the treatment. She has published several papers in outcomes, late effects, and quality of care in cancer patients and provides mentorship to trainees interested in projects in these areas. She has been a member and has held leadership positions at Mayo Clinic and in the various committees in organizations/ societies in hematology and BMT/CT.. She was the working committee co-chair for the Health Services and International Issues Working committee of CIBMTR from 2015 to 2020 and a member of BMT-CTN SOSS Late Effects committee in 2020. As the co-chair of Dissemination and Implementation committee at BMT CTN currently, she leads efforts in improving translation of evidence into practice in the field of BMT. She is the Director of Community or Clinical Practice at ASTCT. About Dr. Alexandra Gomez Arteaga Dr. Alexandra Gomez Arteaga is an Assistant Professor at Weill Cornell Medicine/NewYork-Presbyterian Hospital and directs the Allogeneic Bone Marrow Transplant Service and the Advanced Fellowship in Bone Marrow Transplantation. She earned her MD from Los Andes University, completed her residency at the University of Miami, her Hematology/Oncology fellowship at Weill Cornell, and her BMT advanced fellowship at Memorial Sloan Kettering Cancer Center. Dr. Gomez's research focuses on improving outcomes in allogeneic stem cell transplantation for leukemia and myeloid malignancies, with an emphasis on young adults and alternative donors. Her work also addresses the critical need to decrease disparities in access to transplantation for minority populations, a cause she champions across her clinical practice, research, and advocacy. She currently serves as the Co-Chair for the Junior Faculty Initiative within the ASTCT ACCESS Initiative. About Dr. Andrés Gómez De León Dr. Andrés Gómez De León (@GomezDLeonMD) is an Associate Professor at Universidad Autonoma de Nuevo Leon in Monterrey Mexico and an ASTCT Content Committee member with an interest in acute leukemias and transplant and cell therapies in low and middle income countries.

Join us for an insightful discussion on the connections between cancer and autoimmune diseases with our expert guests, Dr. Tirisham Gyang and Dr. Porter.✨ Dr. Tirisham Gyang is a neuro-immunology specialist and Program Director for the Multiple Sclerosis Fellowship at Ohio State University. She's dedicated to advancing treatments for demyelinating conditions and exploring neurotoxicity linked to immune cancer therapy.✨ Dr. Porter is a Neurology Professor and Director of NeuroOncology at Mayo Clinic Arizona. With over two decades of experience, she's committed to improving the quality of life for brain cancer patients and advocating for diversity in medicine. therapy.

On today's episode, we are joined by Dr. David Lott, a second time guest and fellowship trained laryngologist. As the director of the center for regenerative medicine at Mayo Clinic Arizona, he has gained national attention recently for completing the third laryngeal transplant in the US and the first in someone with active cancer. We have had the pleasure of speaking with Dr. Lott during the preparation stages of this journey and are excited to share his story now that his vision has come to fruition. Enjoy!

Endometriosis (commonly referred to as “Endo”) has a global impact on females of reproductive age. According to the World Health Organization, it affects about 10% of women and girls. What we know as doctors and practitioners who treat people who have endometriosis, is that it is extremely difficult to arrive at this diagnosis due to various various factors.  On average it can take more than 5 years of someone suffering before they have an idea that endometriosis might be the cause. One of the most preventable factors is simply education around what the condition really is, how it can be identified, how it can be clinically diagnosed, and the many ways that its symptoms can be managed.Our guest today is the renowned Dr. Madhu Bagaria. After two rigorous OBGYN residencies and a prestigious 2-year fellowship in minimally invasive gynecological surgery at Mayo Clinic Arizona (where she trained under world-renowned experts like Drs. Louie, Yi, Wasson, Magtibay and Butler), Dr. Bagaria is now the leading specialist in endometriosis at Pelvic Rehabilitation Medicine in NYC. She currently is one of the few people in the world who provides the latest type of laparoscopic excision surgery for endometriosis. Throughout her career, Dr. Bagaria has developed a deep understanding of pelvic pain and endometriosis, conditions that can significantly impact the lives of women. She is a strong advocate for patient education and empowerment, believing that women should be actively involved in making decisions about their healthcare.Dr Bagaria's diverse specializations (minimally invasive gynecology, urogynecology, gynecologic oncology) allow her to provide innovative and compassionate treatment for your pelvic health needs. Before dedicating her practice to pelvic pain and endometriosis, Dr. Bagaria gained valuable experience as a generalist at Mayo Clinic Health System at Austin, MN for 6 years. During this time, she developed a comprehensive understanding of women's health issues, providing care for a wide range of gynecological conditions.Connect with her at:pelvicrehabilitation.com

Brought to you by: Mayo Clinic Talks Podcast HOST: Nicole Nfonoyim-Hara GUEST: Amy Hara, M.D. On this episode of the RISE for Equity podcast, Dr. Amy Hara joins host Nicole Nfonoyim-Hara for an insightful discussion on the topic of leadership in healthcare. Dr. Hara, a member of the Mayo Clinic Board of Governors and Mayo Clinic Arizona's Executive Operations team, shares her experiences and perspectives on what it means to be an effective leader in the ever-evolving healthcare industry. Learn more at https://mcpress.mayoclinic.org/rise-for-equity/    Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.    "For my leadership, I really encourage folks to bring themselves. Because you think differently or because you do this differently,  you would be a great leader. I try to encourage people that's a strength in not trying to mold yourself into something else." -Amy Hara, M.D.

Brought to you by: Mayo Clinic Talks Podcast HOST: Nicole Nfonoyim-Hara GUESTS: Catherine W. Njathi-Ori, M.D. and Natalie H. Strand, M.D. “On a scale of 1 to 10, what's your pain?” If you've just broken a bone or are seeking treatment for endomitosis, it's likely the first question you'll be asked. But what if your pain is dismissed or minimized due to your age, race, or gender? In this episode of the RISE for Equity podcast, host Nicole Nfonoyim-Hara unpacks the latest evidence around bias in pain management—and effective strategies for a holistic approach to care—with Mayo Clinic physicians Catherine Njathi-Ori and Natalie Strand. Catherine W. Njathi-Ori, M.D., is an anesthesiologist specializing in acute pain management based in Rochester, Minnesota. Natalie H. Strand, M.D., is an Associate Professor in the Department of Anesthesiology, Division of Pain Medicine. She serves as the Director of Pain Research and the Director of Neuromodulation for Mayo Clinic Arizona. Learn more at https://mcpress.mayoclinic.org/rise-for-equity/    Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.    “We need to be humble as providers, because there definitely will be cultural influences on how patients are going to respond to how they're feeling…. While we have the visual and the numeric skills, we have to acknowledge that pain is more complex.” — Catherine Njathi-Ori, M.D. “People I think are well-meaning in medicine for the most part. I really believe that. But just because you're well-meaning doesn't mean you're not biased. People often can't see their own blind spots. When you don't have diversity in your division or department, or you don't have diversity on your admissions committees, or you don't have diversity in your surgical teams and anesthesia teams, how is anybody supposed to see their own blind spots?” —Nathalie H. Strand, M.D.

We talked with:Gladys McGarey, M.D., is a pioneer in allopathic and holistic medical movements and continues to practice medicine even now that she is over 100 years old. She is a founding diplomat of the American Board of Holistic Medicine. She is the cofounder and past president of the American Holistic Medical Association. She lives and works in Scottsdale, Arizona. She has cared for thousands of patients and people all around the world and across all life stages from birth to death, where she inspires what she calls living medicine.Larry Bergstrom, M.D., is an assistant professor of medicine at Mayo Clinic in Arizona in the Division of Consultative Medicine. He is the past chair of general internal medicine in Mayo Clinic in Rochester and moved to Mayo Clinic Arizona 2006 to start the integrative medicine program. Dr. Bergstrom sees patients for whom conventional medicine has had insufficient answers, including those with chronic fatigue, chronic pain, autoimmune disease.  He tells his patients that he is not so much focused on treating their disease but rather trying to find ways of helping them become healthy.We talked about:In this episode, Dr. Millstine and her guests discuss:The limits of conventional medicine. Conventional medicine can be passive, Dr. Bergstrom says: You go to the doctor and get a prescription. Dr. Bergstrom and Dr. Gladys believe in empowering their patients, engaging with them and giving them tools to improve their wellness.  A personal approach. Stress has important negative effects on health, but you can't simply direct someone to “Be less stressed.” In fact, Dr. Bergstrom says you can't address stress until you fully understand someone's story: Who they are, how they got there, what's happened to them, and how that's affected their ability to live.Finding your “juice.” Dr. Gladys wants everyone to recognize their “juice” — her term for your reason for living, your source of joy and purpose, and what gets you out of bed in the morning. Physicians often shy away from addressing this aspect of spiritual wellness, Dr. Bergstrom says, because it's messy. But it's essential to understand for whole-person wellness. Can't get enough?Purchase the Mayo Clinic Press book “Live Younger Longer.”Purchase “The Well-Lived Life: A 102-Year-Old Doctor's Six Secrets to Health and Happiness at Every Age.”From Bookshop.org.From Amazon.  From Barnes & Noble.  Want to read more about health topics? Check out our blog.Got feedback?If you've got ideas or book suggestions, email us at readtalkgrow@mayo.edu.We invite you to complete the following survey as part of a research study at Mayo Clinic. Your responses are anonymous. Your participation in this survey as well as its completion are voluntary.

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Dr Jay Pasricha, Chair of the Department of Medicine, Mayo Clinic Arizona, Arizona, USA and Bo Konings, final year medical student and researcher at the Translational Research Centre for Gastrointestinal Disorders (TARGID), KU Leuven University Hospitals, Leuven, Belgium, on the paper "Gastrointestinal syndromes preceding a diagnosis of Parkinson's disease: testing Braak's hypothesis using a nationwide database for comparison with Alzheimer's disease and cerebrovascular diseases" published in paper copy in Gut in November 2023 and available online: https://gut.bmj.com/content/72/11/2103 Please subscribe to the Gut Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest podcast every month. If you enjoy our podcast, please consider leaving us a review or a comment on the Gut Podcast iTunes page (https://podcasts.apple.com/gb/podcast/gut-podcast/id330976727).

Adam J. Milam, MD, PhD is a Senior Associate Consultant in the Department of Anesthesiology and Perioperative Medicine at Mayo Clinic Arizona. Prior to starting this position, he completed his cardiothoracic anesthesiology fellowship at Cleveland Clinic and residency at Cedars-Sinai Medical Center. He graduated from Wayne State University School of Medicine. Prior to medical school, he attended Johns Hopkins University where he graduated with a Bachelor of Arts in Public Health. He also holds a Master of Health Science as well as a Doctor of Philosophy in Public Health from the Department of Mental Health at Johns Hopkins Bloomberg School of Public Health.Dr. Milam has been actively involved in several national and state societies including the American Society of Anesthesiologists, the Society of Cardiovascular Anesthesiologists, the National Medical Association, and the California Society of Anesthesiologists; he serves on committees for each of these organizations. He also is actively engaged in research; Dr. Milam's research is rooted in practices, policies, and interventions to address health disparities and health inequities. He has published over 80 peer-reviewed publications and has more than 75 national, international, and invited presentations. His research has been featured and disseminated in leading public health and medical journals as well as Men's Health, Rolling Stone, and US News & World Report. His work has been used to guide local and state legislation that promote health equity. Dr. Milam's research also explores barriers to and possible strategies to improve diversity in the medical workforce. He has received multiple national awards including the Herbert W. Nickens Scholarship from the Association of American Medical Colleges and the Excellence in Public Health Award from the U.S. Public Health Service Physician Professional Advisory Committee; Dr. Milam is also a member of the Delta Omega Public Health Honor Society. Dr. Milam's Twitter Dr. Milam's Website

Dr. Haden was born and raised in Nebraska.  He completed his Bachelor of Science at Nebraska Wesleyan University.  He then attended the University of Connecticut School of Medicine for a joint MD and Masters of Public Health program.  Dr. Haden completed 18 months of residency training at Georgetown/Providence Hospital in Washington, DC before transferring to the Mayo Clinic Arizona, where he completed his specialty training in Family Medicine.  He is board certified in Family Medicine and has worked for several years in urgent care and primary care. While working as a doctor, he also went to business school and obtained his MBA to help in his entrepreneurial endeavors. He was the founder and CEO of MobileMDs, an on-demand service for doctor's house calls serving travelers at hotels and resorts across the US.  After several years of growing that business, he decided to return his focus to primary care, and restoring the doctor-patient relationship through Direct Primary Care (DPC).Dr. Haden has traveled extensively and even lived abroad for a time in Egypt and Costa Rica.  Over the past 20+ years, he has enjoyed the opportunity to visit Rome, Casablanca, Malta, Gibraltar, Montreal, Ottawa, several parts of India, Nepal, Mexico, Trinidad, and the Dominican Republic. These experiences have helped him to better understand how one's culture can influence health and the treatment preferences of patients. Dr. Haden enjoys working out, visiting family, drinking coffee, playing the drums, driving his electric car, and spending quality time with his wife, daughter and son. He was selected as a 2015-2016 Fellow of the Leonine Forum at the Catholic Information Center in Washington, DC and has volunteered with the Order of Malta Federal Association Auxiliary.---------------------Check out the My DPC Story RESOURCE PAGE HERE!Find a DPC checklist on how to start your own DPC, DPC conference recordings, and more!---------------------LISTENER'S GUIDE!1) RATE and REVIEW our podcast on Apple Podcasts.2) Take a screenshot ***BEFORE you hit submit*** of your review and then email it to support@mydpcstory.comand you'll find the Listener's Guide in your inbox!---------------------HELP FUND THE PODCAST!CLICK HERE to Support the show-------Download Hint's 2023 Employer Trends in Direct Primary Care here: https://bit.ly/3EZAYej Learn more about Med Mastery: HERE Do you have a question for our future guest to answer? Click this link and leave us a voicemail with your question: https://www.speakpipe.com/mydpcstorySupport the showVisit the DPC SWAG store HERE!Let's get SOCIAL! Follow My DPC Story! FACEBOOK * INSTAGRAM * LinkedIn * TWITTER * TIKTOK * YouTube

Sarah Sydlowski, AuD, PhD, MBA is Audiology Director of the Hearing Implant Program and Associate Chief Improvement Officer at the Cleveland Clinic in Cleveland, Ohio. Dr. Sydlowski is Board Certified in Audiology with Specialty Certification in Cochlear Implants. Her clinical and research interests focus on implantable hearing devices, optimization of practice efficiency while maintaining strong outcomes, and development of innovative clinical delivery models. She has earned the Cleveland Clinic Distinguished Educator Certificate and is adjunct faculty at the University of Akron where she teaches the graduate Implantable Technologies course.Dr. Sydlowski completed her clinical doctorate at the University of Louisville, her externship at Mayo Clinic Arizona, and her PhD at Gallaudet University. Most recently, she completed her executive MBA at the Weatherhead School of Management at Case Western Reserve University where she was the recipient of the EMBA Leadership Award.Dr. Sydlowski has been very active in professional organizations, serving on the American Academy of Audiology Board of Directors as a member-at-large (2015-2018) and currently as Immediate Past President. She is a past president of the Ohio Academy of Audiology and was Co-Chair of the American Cochlear Implant Alliance Program Committee in 2021. She is currently Co-Chair of the Hearing Health Collaborative, a think tank of audiologists, otologists, and patient advocates charged with developing a blueprint for changing the landscape of hearing healthcare. She is also principal investigator of a study focused on integration of tablet-based hearing screeners in primary care and geriatric medicine practices. Together with her physician co-investigators, Dr. Sydlowski aims to quantify the feasibility and impact of prioritizing the identification and management of hearing loss with referring providers.In her role as Associate Chief Improvement Officer, Dr. Sydlowski works closely with CI specialists across the organization to develop a culture of improvement where every caregiver is capable, expected, and empowered to make improvements every day. Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

The comprehensive geriatric assessment is one of the cornerstones of geriatrics.  But does the geriatric assessment do anything?  Does it improve outcomes that patients, caregivers, and clinicians care about? Evidence has been mounting about the importance of the geriatric assessment for older adults with cancer, the subject of today's podcast.  The geriatric assessment has been shown in two landmark studies (Lancet and JAMA Oncology) to reduce high grade toxicity, improve patient and caregiver satisfaction, and improve completion of advance directives (can listen to our prior podcast on this issue here).  Based on this surge in evidence, the American Society of Clinical Oncologists recently updated their guidelines for care of older adults to state that all older adults receiving systemic therapy (including chemo, immuno, targeted, hormonal therapy) should receive geriatric assessment guided care.  We talk about these new guidelines today with William Dale, a geriatrician at City of Hope and lead author of the guideline update in the Journal of Clinical Oncology, Mazie Tsang, palliative care/heme/onc physician-researcher at Mayo Clinic Arizona who authored a study of geriatric and palliative conditions in older adults with poor prognosis cancers published in JAGS, and John Simmons, a retired heme/onc doctor, cancer survivor, and patient advocate.  We talk about: What is a practical geriatric assessment and how can busy oncologists actually do one? (hint: 80% can be done in advance by patients or caregivers) Why is it that some oncologists are resistant to conducting a geriatric assessment, yet have no problem ordering tests that cost thousands of dollars? What can you do with the results of a geriatric assessment? How does the geriatric assessment lead to improved completion of advance directives, when the assessment doesn't address advance care planning/directives at all? How does palliative care fit into all this?  Precision medicine? What groups are being left out of trials? What are the incentives to get oncologists and health systems to adopt the geriatric assessment?   And Mazie, who is from Hawaii, requested the song Hawaii Aloha in honor of the victims of the wildfire disaster on Maui.  You can donate to the Hawaii Red Cross here. Aloha, -@AlexSmithMD   Additional Links: Brief ASCO Video of how to conduct a practical geriatrics assessment Brief ASCO Video of how to use the results of a practical geriatrics assessment Time to stop saying the geriatric assessment is too time consuming    

This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona. Griswold discussed the latest updates from ASCO in PARP inhibitors for prostate cancer, as well as what's on the horizon in this quickly-evolving treatment space.

In value-based care, true leadership emerges from the depths of the heart, where empathy, compassion, and authenticity converge to illuminate the path of positive change. Purpose-driven leadership can not only revolutionize community health but also create a ripple effect that reaches every corner of society. At the intersection of purpose, compassion, and community lies a transformation of our healthcare system with a tangible impact on the well-being of individuals, families, and neighborhoods. Now is the time for healthcare leaders to harness the power of the heart to shape a healthier and more harmonious world for all.  The heart's power of purpose knows no boundaries, for it holds the strength to heal, inspire, and connect the threads of humanity. Joining us this week on the Race to Value is Mikelle Moore, a nationally recognized health executive with more than 25 years of experience impacting communities through forward-thinking, collaboration, and leadership. Mikelle has payer, provider, business and start-up experience in healthcare having served in executive leadership at Intermountain Health, an integrated system serving an 8-state region. During her tenure at Intermountain, she served as Chief Community Health Officer and as the first female CEO of the system's flagship hospital. In addition, Mikelle has worked in contracting for a provider-owned health plan and in strategy for Mayo Clinic Arizona. As a thought leader in the space, Mikelle knows the value in moving from healthcare to health. In this week's episode, prepare to be inspired and enlightened by Mikelle's heartfelt exploration of “The Power of Purpose:  Transforming Community Health Through Leadership of the Heart.”   Episode Bookmarks: 01:30 Introduction to Mikelle Moore, a nationally-recognized VBC executive leading system change to improve population health outcomes. 03:15 Support Race to Value by subscribing to our weekly newsletter and leaving a review/rating on Apple Podcasts. 04:00 Broadening the scope of care delivery in health systems to address the determinants of health through equity, impact investments, and ESG factors. 06:00 Mikelle discusses her leadership journey as an expression of authenticity and purpose to right the wrongs of a broken system. 08:00 Intermountain Health as a leading health system that is designed for a consumer-provider approach to improving health care. 09:00 Advocating for improvements in the variability of care and the reduction of wasteful healthcare utilization. 09:30 Listening to the community in the strategic planning of a hospital. 10:00 Pivoting from “sick care” to “health care.” 10:45 The realization that health disparities were far reaching beyond just the care delivered, e.g. poverty, homelessness. 11:00 “If we want to be health leaders that are making healthcare better, we have to be champions for addressing disparities in underserved and marginalized communities.” 13:00 Finding common ground with Community Benefit Organizations (CBOs). 14:00 Mikelle shares his insights on the importance of relationship-building in community partnerships. 16:00 How the principles of collective impact forged new community partnerships to address behavior health and SDOH. 17:00 Defining success by really understanding the problem and what issues get in the way (e.g. how nonmedical issues such as homeless and social isolation impact health outcomes) 19:00 Developing a system of communication and data sharing between the CBO and health system that is centered on patient needs. 20:00 The Alliance for the Determinants of Health as a vehicle to address social needs to improve health. 21:00 The impact of institutional racism on health equity. 24:00 Viewing social factors in society as a lens to view and understand racism. 25:00 “Inequities are often delivered at a subconscious level. It is our accountability to identify those disparities and build systems of care to prevent them from occurring.”

Did you know a high percentage of women experience some form of sexual dysfunction? Did you also know that the rate increases even more when cancer treatment, like cervical cancer, is involved? In this episode, Cervivor Podcast Host, Joslyn Paguio has a candid conversation with Dr. Tali Sobel, a Women's Health Internist at the Mayo Clinic. You'll hear them get down to the basics of understanding sexual dysfunction, how it happens, ways we can alleviate some of the pain and discomfort women experience, and what professional resources are out there to better assist women in reclaiming their sexual confidence. Plus, you'll hear some of the recommended products listed below to discuss with your doctor! Good Clean Love Lelo Mayo Clinic Store Mystery Vibe (Use Code: Cervivor15 to get 15% off Tenuto 2, Crescendo 2 and Poco) Ohnut Uber Lube (Use Code: CERVIVOR to get 10% off) Dr. Tali Sobel is a women's health internist specializing in sexual health and menopause at Mayo Clinic Arizona. She is originally from Washington, DC. She received a degree in psychology at the University of Michigan for her undergraduate studies and attended Georgetown University for medical school. She then moved to Baltimore, Maryland for residency in internal medicine at Johns Hopkins Bayview. She completed a women's health fellowship at Johns Hopkins following residency and is a North American Menopause Society certified menopause specialist. She recently moved to Phoenix, Arizona with her husband and dog and enjoys hiking, exploring the beautiful Southwest, and spending time with her family. Did you connect with this episode? Share your thoughts with us on social media using #CervivorPodcast or by emailing us.  For more Cervivor-related content, check out: Cervivor.org. Follow Cervivor on all social media platforms. If you would like to be interviewed as a potential guest for an upcoming episode or would like to request a speaker or topic for a future podcast episode, email us at info@cervivor.org. --- Support this podcast: https://podcasters.spotify.com/pod/show/cervivor/support

Vascular Origin Stories is a podcast series that explores the fun and engaging stories that shaped vascular surgery.   Today's episode will be the second part of a multi-episode series exploring how the young battalion surgeons serving in MASH units in the Korean war pioneered wartime vascular repair. Today we'll explore in detail the individual stories of adversity, courage, and perseverance that led to the re-introduction of arterial repair in the military. Representative images, significant sources for the episode, and a complete reference list can be found on the episode webpage.   Author + Host: Marlene Garcia-Neuer (@GarciaNeuer) is a PGY1 General Surgery Resident at Mayo Clinic Arizona.   We are calling all medical students! Submit your questions for the mailbag episode! Ask us any question related to vascular surgery, and have it answered on the podcast.  Include the following Your name, school, and year Who do you want to address the question to (resident, fellow, attending, or someone specific) Please send them in writing or voice-recorded format.   Please share your feedback through our Listener Survey! Follow us on Twitter @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and #jointheconversation.   Music by ZakharValaha and Kaazom from Pixabay,  

In this episode, Mohsen Khosravi Maharlooei joins us to discuss the role of the thymus in spontaneous development of a multi-organ autoimmune disease in human immune system mice. Ask the Expert is a ~30 minute digital cafe experience where scientists and grad students can meet and exchange with thought leaders in the field of type 1 diabetes. Link below to sign up for a seat in the cafe!

Guest host Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss several crucial studies that will be presented at the 2023 ASCO Genitourinary Cancers Symposium, including ARASENS, TRITON3, and others in prostate cancer, as well as novel therapies in mRCC and urothelial carcinoma. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to welcome Dr. Jeanny Aragon-Ching, a medical oncologist and the clinical program director of the Genitourinary Cancers Program at the Inova Schar Cancer Institute in Virginia.   Today we will be discussing key abstracts in genitourinary oncology that will be featured at the 2023 ASCO Genitourinary Cancers Symposium.   Our full disclosures are available in the show notes, and disclosures for all guests on the podcast can be found on our transcripts at asco.org/podcasts. Jeanny, it is great to have you on the podcast today.   Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal, for having me.  Dr. Neeraj Agarwal: So Jeanny, let's begin with Abstract 15 on the update on the ARASENS trial, which Dr. Maha Hussain will present [at the meeting]. In March ‘22, as we know, almost a year ago, the results of the ARASENS trials were published in the New England Journal of Medicine. Darolutamide, which is an AR signaling inhibitor plus androgen deprivation therapy plus docetaxel chemotherapy, significantly reduced the risk of death by 32.5% versus placebo plus ADT plus docetaxel. The effect of triplet therapy, including darolutamide on overall survival, was consistent across prespecified subgroups. However, survival outcomes by disease volume were not reported at the time. Can you please tell us about Abstract 15?  Dr. Jeanny Aragon-Ching: Yeah, thank you so much, Neeraj, I would be happy to. So, this new data is actually very crucial for all clinicians. The title of this abstract is “Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study.” So, as a quick reminder, in this trial, patients were randomized 1:1 to the standard dose of darolutamide 600 milligrams twice daily or placebo with ADT and docetaxel in the metastatic hormone-sensitive prostate cancer setting.    Now remember, too, high volume disease was defined per the charted criteria, which is visceral metastases and/or four or more bone lesions, of which at least one or more has to be beyond the vertebral column or pelvis. 8And high-risk disease was actually defined per the LATITUDE criteria, which is any two or more of the following three factors: Gleason scores eight or more, bone lesions that are three or more, and the presence of measurable visceral metastases. Of all the 1,305 patients, 77% of them were actually classified as having high-volume disease, and 70% of them had high-risk disease. So, in both of these high-volume and low-volume disease patients, the triplet therapy darolutamide, ADT, and docetaxel actually improved overall survival and hazard ratio was 0.69 and 0.68, respectively. Compared to the placebo and ADT, and docetaxel arm. So overall survival improvement was also significant in patients across all risk, high-risk, or low-risk disease.   Dr. Neeraj Agarwal: So, Jeanny, this is great news. So, the main message from this abstract for our audience is that triplet therapy of darolutamide plus docetaxel plus ADT is more efficacious than the doublet of ADT plus docetaxel chemotherapy, regardless of disease volume or risk status.   One important caveat I would like to note is that triplet therapy with the darolutamide was not compared with the doublet therapy of ADT plus darolutamide or any androgen receptor signaling inhibitor such as abiraterone or apalutamide or enzalutamide, all of which have shown benefit consistently, regardless of volume status, and in the case of abiraterone, also in the context of high-risk disease setting, as we saw in the LATITUDE trial.  Dr. Jeanny Aragon-Ching: Absolutely. I agree with that, Neeraj. Those are important points to consider.   Now, moving on to a different setting in prostate cancer across the disease continuum, let's discuss Abstract 18, titled “Rucaparib for Metastatic Castrate-Resistant Prostate Cancer.” This is TRITON3 entering overall survival and efficacy of rucaparib versus docetaxel or second-generation engine pathway inhibitor therapy, which will provide us with some additional data regarding overall survival. Neeraj, based on this new abstract, can you tell us more about TRITON3, which will be presented by Dr. Alan Bryce and colleagues from the Mayo Clinic Arizona?  Dr. Neeraj Agarwal: Of course. So TRITON3 is a randomized multicenter open-label phase 3 trial where rucaparib was compared with the physician choice of docetaxel chemotherapy or abiraterone or enzalutamide in those patients who had not received chemotherapy in the metastatic castration-resistant prostate cancer setting, and they had to be progressing on a prior androgen receptor signaling inhibitor in any setting prior. So, they just had to have disease progression either in the hormone-sensitive setting or CRPC setting on one of the AR inhibitors, and they had to have a BRCA1, BRCA2, or ATM alteration.   So, in this context, these patients were randomized to rucaparib versus physician's choice of agent, which could again be docetaxel chemotherapy, abiraterone, or enzalutamide. So, OS maturity is 54% in BRCA group and 59% in the intention to treat population. In BRCA1 and BRCA2 populations, radiographic PFS, which was the primary endpoint, was 11.2 months in rucaparib group and 6.4 months in the physician choice arm. In the intention to treat population where you include all patients BRCA plus ATM patients, ATM positive patients. Radiographic PFS was 10 months almost versus 6.4 months with standard of care. And both were statistically significant as well as clinically meaningful improvement in the radiographic progression-free survival with rucaparib over physician's choice of either docetaxel or enzalutamide, or abiraterone. I would like to note that most frequent toxicity which we see with this group of agents is most frequent grade III or more toxicity was anemia, which was present in approximately 24% patients treated with rucaparib.  Dr. Jeanny Aragon-Ching: Yeah. This is a really exciting update, Neeraj. What do you think is the key takeaway from this abstract?  Dr. Neeraj Agarwal: The key takeaway is that TRITON3 trial met its primary endpoint, and rucaparib significantly improves radiographic progression-free survival in BRCA mutation-positive patients or BRCA ATM-positive patients. Overall survival is still immature, and these results further establish rucaparib as one of the standard of care options in those patients who have metastatic CRPC with prior treatment with the AR signaling inhibitor and who harbor one of the BRCA mutations or BRCA NAT mutations.   So, Jeanny, before moving on to the renal cell carcinoma section in this podcast, there is an Abstract in prostate cancer talking about correlation between the source of funding and disparities among patients with advanced prostate cancer. So, I'm referring to that Abstract 40, titled “Source of Funding and Enrollment Disparity in Prostate Cancer Clinical Trials.” I thought this was an interesting abstract. Could you please tell us more about this abstract?  Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in Abstract 40, Dr. Riaz and Dr. Bryce, and colleagues actually looked at phase II and III clinical trials that involved prostate cancer patients that reported on patients with age by 65 years, and they got the data from the MEDLINE and Embase databases. Trials recruiting from the United States were considered eligible for analysis by race and ethnicity. So, in terms of race and ethnic enrollment, they found that black patients were significantly underrepresented in the industry's funded trials. Notably, no significant disparity was observed in the US government-funded trials, but Hispanics were also significantly underrepresented in industry-funded clinical trials. However, no significant disparity was seen in terms of older adults overall and by funding sources. Remarkably, Black patients' representation in industry-funded prostate cancer trials has actually decreased over the last three decades.  Dr. Neeraj Agarwal: That's concerning. So, what is your key takeaway from this trial, Jeanny?  Dr. Jeanny Aragon-Ching: The key message here is that Black and Hispanic men with prostate cancer are significantly less likely to be included in industry-sponsored clinical trials. A bigger concern is that black patients' representation actually continues to decline over time. So these results warrant a really more proactive role by regulatory bodies to ensure that a proportional representation of minorities in the industry trials, which in turn will make these results more applicable to a wider entire population of men with prostate cancer.  Dr. Neeraj Agarwal: Thanks, Jeanny. Let's move on to renal cell carcinoma. I saw some innovative research correlating the efficacy of immune checkpoint inhibitors with the time of the day these checkpoint inhibitors were administered. So, interestingly, there were two studies from two different groups of investigators showing very similar results. Please tell us about this innovative research correlating outcomes with immune checkpoint inhibitors with the time of the day these medicines or these drugs were infused into the patients.   Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. I think they're very exciting and interesting. So there's actually two abstracts, so Abstract 681 and 678, which we, of course, can discuss separately. So, let's probably start first with Abstract 678. Neeraj, do you want to explain to us further about this abstract?  Dr. Neeraj Agarwal: Yes. When our center participated in that abstract, which was led by Dr. Nazli Dizman from Yale University, Dr. Dizman and colleagues examined the relationship between the time of the administration of immune checkpoint inhibitors, or ICIs, as we call them, during the time of the day, and outcomes in patients with metastatic renal cell carcinoma. So, I'd like to point out that previously Dr. Qian and colleagues reported an association between the time of day of immunotherapy infusion and survival outcomes in patients with metastatic melanoma.   In this study, Dr. Dizman and colleagues, which included our center also, patients with metastatic RCC who received nivolumab with or without ipilimumab– so these patients all received either nivolumab alone or without ipilimumab. And patients who received less than 25% of infusion after 4:30 pm. were assigned to the early-time of infusion group. So, if they have received less than 25% infusion of these immunotherapies after 04:30 pm in the evening, they belong to the early infusion group, and the rest were assigned to the late infusion group.  In the univariate analysis, numerically higher objective responses and time to treatment failure were observed in the early infusion group compared to the late infusion group. So, differences were 33% versus 25% in objective responses in early versus late infusion group. If you look at time to treatment failure, 8.3 months versus 4.4 months in early versus late infusion group. In the multivariate models, which took into account the clinical characteristics such as age, gender, line of treatment, IMDC risk category, histological subtypes, there was a trend towards improved outcomes in those who received these infusions with ICIs early in the day. So, Dr. Dizman concluded that larger randomized and controlled investigations are warranted to examine the impact of this chronal modulation, if you will, on the efficacy of immune checkpoint inhibitors in metastatic RCC sets.  Dr. Jeanny Aragon-Ching: Yeah, this is very interesting data, Neeraj. And that actually resonates closely with this other abstract by Fernandez Manias and colleagues in Abstract 681. So, in this abstract, the primary outcome was overall survival, but they did look at other secondary endpoints like time on treatment, time to the next treatment, and overall response rates. Now, because of the small number of events, the authors actually focused on just patients who received second-line immune checkpoint inhibitors. And what they did was they looked at patients who received overall more than 20% of their infusions after 04:30 pm, and they found that those who did receive actually fewer infusions had a significantly shorter time on treatment and had a worse overall survival. And similar results were seen when they looked at those who got more than 50% of their dose of checkpoint inhibitors that were administered after 04:30 pm, so interestingly enough, there was a 16% increase in the risk of death for each 10% increment of checkpoint infusion after 04:30 pm. So the key message here is that administration of checkpoint inhibitors after 04:30 pm is associated, unfortunately, with inferior outcomes. Now, these results should, of course, be further considered in the organization overall of the outpatient clinic as it can impact patient survival and outcomes.  Dr. Neeraj Agarwal: Very interesting. So similar results from two independent groups of investigators from two different continents obviously made this research area very appealing and pertinent. Ideally, I think these results should be validated prospectively, but that will take time. But investigators who have already lagged multiple phase III trials should explore validating these results in the last phase 3 trials which have already been reported and where the data on the timing of infusion is available. Once validated, I think these results may profoundly influence how we organize, as you said, Jeanny, the outpatient scheduling of these checkpoint therapy infusions compared to those who are not checkpoint inhibitors. I think this is going to have very interesting data overall, no doubt.   Before moving onto bladder cancer, I would like to discuss an important abstract related to testicular cancer patients titled “Longitudinal Evaluation of Plasma MicroRNA-371 to Detect Minimal Residual Disease and Early Relapse of Germ Cell Tumors.” Could you please tell us more about this abstract?  Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this is a very interesting up-and-coming Abstract, it's number 407, which will be presented by Dr. Lucia Nappi and colleagues. In this study, clinical patients with stage I germ cell tumor with available plasma samples after they underwent radical orchiectomy were all included. So, they looked at sensitivity, specificity, negative, positive predictive values, an area under the curve in predicting tumor recurrence, and they evaluated the microRNA-371, I'll just call it and truncate it as miR-371, and compared the same operating characteristics of current gold standard diagnostic tests. Relapse-free survival was correlated to post-orchiectomy miR-371 status, which could be either positive or negative.   So, at a median follow-up of 41 months, 101 patients with clinical stage one germ cell tumor were included. About 35% of them experienced a disease relapse during that time of follow-up. Now, what they found was miR-371 was positive in about 63% of the relapsed patients, and the miR-371 positivity preceded clinically evident disease by a median of about three months. The specificity and positive predictive values were 100%, sensitivity was like 63%, and negative predictive value was 83.5%, so very high. No false positive results were seen. And, the authors reported that the recurrence-free survival of the patients who had positive post-orchiectomy miR-371 was significantly shorter compared to those patients who had a negative biomarker for the miR-371. So, they concluded that the miR-371 sensitivity correlated with the tumor burden, time between tumor relapse, the microRNA testing, and histology. It was notably a little bit more sensitive in non-seminomas compared to those who had seminoma.  Dr. Neeraj Agarwal: Interesting findings, indeed. So, Jeanny, what is the take-home message from this abstract?   Dr. Jeanny Aragon-Ching: Yeah, so I think the key takeaway is that microRNA-371 seems to be a good test, like a biomarker for predicting disease relapse in patients with early-stage germ cell tumor. So, additionally, its high specificity and positive predictive value in predicting relapse could really be used and utilized to guide adjuvant therapy, selections, and decisions after orchiectomy. Further validation in other studies, such as swab 1823, are currently ongoing or planned to validate its clinical utility.   So Neeraj, moving on to bladder cancer, the last abstract I'd like to mention before we wrap up the podcast is Abstract 563, titled “Utility of ctDNA in Predicting Outcome and Pathological Complete Response in Patients with Bladder Cancer as a Guide for Selective Bladder Preservation Strategies.” Neeraj, can you tell us more about this abstract?  Dr. Neeraj Agarwal: Sure. So, this study was led by Dr. Lars Dyrskjøt. He and colleagues evaluated the prognostic value of circulating tumor DNA, or ctDNA, in predicting recurrence in a cohort of 68 patients with muscle-invasive bladder cancer who received new adjuvant chemotherapy prior to cystectomy. So ctDNA was analyzed two times at baseline before new adjuvant chemotherapy and then before surgery or before cystectomy. So, patients had ctDNA assessed before neoadjuvant chemotherapy and then before cystectomy after completion of new adjuvant chemotherapy. At baseline, of the 64 patients, around 60% were ctDNA negative, and 40% were positive for ctDNA. So of those patients who were ctDNA negative, 84% achieved pathologic complete response, while in those who tested ctDNA positive, only 35% achieved their pathologic complete response after surgery.   Prior to surgery, 84% of patients were ctDNA negative, and 81% achieved pathologic complete response. While none of the ctDNA-positive patients who were positive before surgery and after neoadjuvant chemotherapy, none of them achieved pathologic complete response, which translates into a positive predictive value of 100% and a negative predictive value of 81% for this test. So based on both ctDNA time points, the probability of ctDNA negative patients to achieve a pathologic complete response was significantly higher than ctDNA positive patients.   At a median follow-up of 59 months, ctDNA-positive patients without pathologic complete response demonstrated significantly lower recurrence-free survival and overall survival compared to those who were ctDNA negative. So, I want to repeat that, at a longer follow-up, which Dr. Dyrskjøt will be presenting, ctDNA positive patients without pathologic complete response had significantly lower recurrence-free survival and overall survival compared to ctDNA negative patients. Furthermore, ctDNA status at baseline, which is before neoadjuvant chemotherapy and before cystectomy, was a better predictor of recurrence-free survival compared to pathologic complete response, which is a remarkable finding here, although it's a smaller data set.  Dr. Jeanny Aragon-Ching: Agree completely, Neeraj. So, I think the importance here, too, is upon prospective validation in larger data sets, we will find that a negative ctDNA test would help in identifying patients who can benefit more from bladder-sparing strategies.   Neeraj, any final thoughts before we wrap up the podcast today?  Dr. Neeraj Agarwal: Before I share my final thoughts, Jeanny, I would like to thank you for joining us and sharing your insights. I always find them very valuable. So, thank you so much for taking the time.   I would like to wrap up the podcast by saying we are seeing an explosion in the development of novel therapeutic approaches for our patients with genitourinary cancers. At the 2023 ASCO GU meeting, we will have multiple studies with practice-impacting data presented by investigators from around the world. I urge our listeners to come and join us in the meeting not only to celebrate these successes but also to help disseminate these cutting-edge data to practitioners and maximize the benefit for our patients across the globe.   I would like to thank our listeners for joining us today. You will find links to the abstracts which we discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you so much.    Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.    Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     Find out more about today's speakers:   Dr. Neeraj Agarwal  @neerajaimms  Dr. Jeanny Aragon-Ching  Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:   Dr. Neeraj Agarwal:    Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences   Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas   Dr. Jeanny Aragon-Ching:    Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, AstraZeneca/MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis   Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb , Astellas/Seattle Genetics   Travel, Accommodations, Expenses: Dendreon, Algeta/Bayer, Bristol Myers Squibb, EMD Serono, Astellas Pharma    

In this episode of The Emoroid Digest Podcast we discuss the new joint guidelines by the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) on anticoagulants and antiplatelets in the peri-endoscopic period Neena Abraham is a Professor of Medicine at Mayo Clinic Arizona, and a Consultant in the Divisions of Gastroenterology and Hepatology, within the Department of Medicine, and Health Care Policy Research in the Department of Quantitative Health Sciences. She is the first female Director of the ACG Institute for Clinical Research and Education.    Host: Dr. Chuma Obineme (GI Fellow) –  https://twitter.com/TypicallySilent   Co-Host: Dr. Jason Brown - https://med.emory.edu/directory/profile/?u=JMBROW2  Guest: https://twitter.com/NeenaSAbrahamMD Link to Guideline: https://journals.lww.com/ajg/Fulltext/2022/04000/American_College_of_Gastroenterology_Canadian.16.aspx Link to Dissemination Tool: https://journals.lww.com/ajg/pages/articleviewer.aspx?year=2022&issue=04000&article=00001&type=Fulltext Link to Emoroid Digest visual Summary: https://twitter.com/EmoryGastroHep/status/1537265031406047233?s=20&t=_nzwjD2vq1k02iJ1CL4M7Q Link to Emoroid Digest Website: https://med.emory.edu/departments/medicine/divisions/digestive-diseases/education/emoroid-digest.html

We welcome in another NBA season with an analysis of how COVID-19 impacted the health of NBA players during the shortened 2020-21 season.  Dr. Anikar Chhabra, MD from Mayo Clinic Arizona and his colleagues published “Effect of a Condensed NBA Season on Injury Risk - An Analysis of the 2020 Season and Player Safety” in OJSM in September.  Dr. Chhabra joins us to discuss his findings that the injury rate did increase during this shortened season that featured more back-to-back games and games per week than usual in addition to a shorter off-season.  He talks about how this trend has been seen in prior condensed seasons, the effects of inadequate rest not only with an increased workload but also with the demands of the COVID-19 testing protocol, and how these results may apply to our youth athletes who are under increasing pressure to focus on a single sport year-round, a hot topic in Sports Medicine known as Sport Specialization.

Vascular Origin Stories is a podcast series that explores the fun and engaging stories that shaped vascular surgery. Today's episode will be the first part of a multi-episode series exploring how the young battalion surgeons serving in MASH units in the Korean war pioneered wartime vascular repair. This episode introduces the Mobile Army Surgical Hospital (MASH), as well as some of the real-life stories from the surgeons unknowingly changing the field of medicine, which inspired the hit movie and TV series M*A*S*H.  We'll look at what caused arterial repair to be removed from the army surgical handbook after WWI and how changing medical education helped create the environment for ingenuity in the MASH units. In part 2, we'll explore in detail the individual stories of adversity, courage, and perseverance that led to the re-introduction of arterial repair in the military. Major sources for the episode are linked below, and a full reference list can be found at the bottom of the page. Articles In Ukraine, Gruesome Injuries and Not Enough Doctors to Treat Them, by Michael Schwirtz and Lynsey Addari Korea, M*A*S*H, and the accidental pioneers of vascular surgery by Dr. Steven Friedman, MD Books Of Life and Limb: Surgical Repair of the Arteries in War and Peace, 1880-1960 by Dr. Justin Barr, MD, PhD MASH: An Army Surgeon in Korea by Dr. Otto Apel, MD and Pat Apel MASH: A Novel About Three Army Doctors  by Richard Hooker References  Robinson, A. Galen: Life Lessons from Gladiatorial Contests. The Lancet Perspective. Vol 382, Is. 9904. November 2013. Friedman, S.G. A History of Vascular Surgery. Futura Publishing. 1989. Van Way, C. War and Trauma: A History of Military Medicine. Mo Med. 2016 Jul-Aug;113(40:260-263 Hernigou, P. Ambroise Pare II: Pare's contributions to amputation and ligature. Int Orthop. 2013 Apr; 37(4): 769-772  Van Way, C. War and Trauma: A History of Military Medicine- PArt II. Mo Med. 2016 Sep-Oct; 113 950:336-340 Apel, O. Apel, P. MASH: An Army Surgeon in Korea. The University Press of Kentucky. 1998.  King, B. Jatoi, I. The Mobile Army Surgical Hospital (MASH): A Military and Surgical Legacy. Journal of the National Medical Association. Vol. 97, No 5. May 2005. Friedman, S.  Korea, MASH and the Accidental Pioneers of Vascular Surgery. Journal of Vascular Surgery. 2007.  Wesselingh, R. From Milites Medici to Army Medics- A two Thousand Year Tradition of Military Medicine. Journal of Military and Veterans' Health. Vol 16, No 4 Gabriel, R. Between Flesh and Steel: A History of Military Medicine from the Middle Ages to the War in Afghanistan. Potomac Books. 2016 Jorgensen,T.J. How Marie Curie Brought X-Ray Machines To the Battlefield. Smithsonian Magazine. Oct 11. 2017 Of Life and Limb: Surgical Repair of the Arteries in War and Peace, 1880-1960. Joseph Barr. University of Rochester Press; 1st edition. November 1, 2019.  Duffy, T.P. The Flexner Report- 100 Years Later.  Yale Journal of Biological Medicine. 2011 Sep;84(3): 269-276  Andrew Dale. Band of Brother: Creators of Modern Vascular Surgery. Deweese. 1996 John Kobler. The Reluctant Surgeon, a Biography of John Hunter. Doubleday and Company. 1960 Eugene Custers, Ollen ten Cate.The History of Medical Education in Europe and the United States, With Respect to Time and Proficiency. Academic Medicine. March 2018-Vol. 93 Is. 3S Kapp, K. Talbot, G. John Hunter, The Father of Scientific Surgery. The American College of Surgeons. Poster CC2017  “Alpha Omega Alpha' History”. Website Kenneth M. Ludmerer. Learning to Heal: The Development of American Medical Education. Basic Books, Inc., Publishers. New York. 1985 Richard Hooker and WC Heinz.  MASH: A Novel About Three Army Surgeons. Pocket Books. 1968.  Jahnke Jr., E.J., Seeley S.F. Acute vascular injuries in the Korean War: an analysis of 77 consecutive cases. Ann Surg. 1953; 138: 158-177 Author + Host: Marlene Garcia-Neuer (@GarciaNeuer) is a PGY1 General Surgery Resident at Mayo Clinic Arizona. Calling all medical students! Submit your questions for the mailbag episode! Ask us any question related to vascular surgery, and have it answered on the podcast. Include the following: Your name, school, year, and to whom you want to address the question (resident, fellow, attending, or someone specific). Send them in writing or voice-recorded format.  Send them to audiblebleeding@vascularsociety.org. Follow us on Twitter @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and #jointheconversation. Credits: Author: Marlene Garcia-Neuer Editor: Sharif Ellozy Reviewer: Eilidh Gunn Music and Sound Effects from Pixabay, special thanks to ZakharValaha and BlenderTimer.

Date: June 12th, 2022 Reference: Finfer et al. Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults. NEJM 2022. Guest Skeptic: Dr. Aaron Skolnik is an Assistant Professor of Emergency Medicine at the Mayo Clinic Alix School of Medicine and Consultant in the Department of Critical Care Medicine at Mayo Clinic Arizona.  He is board certified […]

Britany McElroy is the Operations Administrator of the Hematology & Oncology at Mayo Clinic Arizona. She joins episode 11 of The Health Conscious Podcast to discuss the central role of patient access in clinical operations, and also how incoming administrative fellows can maximize their fellowship experience. 

Timestamps:00:00 Intro01:24 Why does clinical context matter for what test clinicians order?08:41 What determines what kind of test to order?13:07 How does the communication happen between the lab and the clinician? How should it happen to provide best care for the patient?18:21 What do you think about for the future of ordering laboratory tests? 21:59 Outro

In this episode Dr. Maxwell Cooper (TY-Radiology Intern at Emory) and Dr. Nikita Ashcherkin (Medicine Intern at Mayo Clinic Arizona) discuss the big transition from medical school to intern year. They provide advice for preparing for intern year, how to tackle the first month, and ways to grow during intern year. To learn more about DaVinci Academy visit: https://www.dviacademy.com/ *Views expressed in this podcast are those of the individuals, not their respective institutions eBooks for anatomy and biochemistry available on: Google Play: https://play.google.com/store/books/author?id=Maxwell+Cooper+M.D Amazon: https://www.amazon.com/M.D.-Maxwell-Cooper/e/B086XHSK3R Facebook: https://www.facebook.com/dviacademy Instagram: https://www.instagram.com/davinci_academy1/ Twitter: https://twitter.com/DviAcademy LinkedIn: https://www.linkedin.com/company/davinci-academy---dviacademy.com  

In this second of four special episodes highlighting the USCAP 2021 Long Course on Pulmonary Pathology, our host is joined by two distinguished faculty: Dr. Andrew Churg of the University of British Colombia and Dr. Maxwell Smith from the Mayo Clinic Arizona. The two international experts on interstitial lung disease (ILD) share their valuable perspective on “where we are and where we need to go” in our approach to the diagnosis and classification of hypersensitivity pneumonitis (HP) and usual interstitial pneumonitis (UIP). See acast.com/privacy for privacy and opt-out information.

Professor, Chair of Medicine, Mayo Clinic Arizona

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Javier Magrina to discuss robotic vs open radical hysterectomy in pathology interrogation. Dr. Magrina is a Professor of Obstetrics and Gynecology at Mayo Graduate School of Medicine, and the recipient of the Barbara Woodward Lips Professorship. He is a staff consultant at Mayo Clinic Arizona. Conclusions: . robotic radical hysterectomy results in inferior survival as compared to laparotomy. . robotic radical hysterectomy for early cervical cancer

Andrew S. Gallan, Ph.D. is an Assistant Professor of Marketing and Director, Center for Services Marketing & Management, at the College of Business at Florida Atlantic University, Boca Raton, FL. His research interests are in the areas of innovation, design, and patient experience in health care, which explore the transformative potential of services; and, the use of data analytics to uncover insights into innovative new business strategies. Andrew's collaborations with a variety of health care organizations, including Mayo Clinic Arizona, Advocate Health Care, the Patient, and Family-Centered Care Innovation Center at the University of Pittsburgh Medical Center, and University of Chicago Medical Center, have resulted in support for students, teaching, advising, and research.​ Dr. Gallan has published in Patient Experience Journal, Journal of the Academy of Marketing Science, California Management Review, and other top services and health care journals. Andrew is also the principal of a patient experience analytics and advisory company, Dignity in Action, Inc. Here in Episode #87, Andrew starts our show with a mindset around servant leadership; he walks us through his career transition going from over 20 years working in the industry to publishing industry-changing research for healthcare; Andrew highlights the work that he's leading around patient experience and customer relationship management; Andrew teaches us why we should not be focused on patient satisfaction; he shifts our mindset around the difficulties of being a patient; he shares his biggest learnings, losses, and successes as a healthcare leader; Andrew teaches us that it's never too late to live your goals; he emphasizes the value of “nothing about me, without me”; he highlights telehealth as the biggest opportunity and challenge for healthcare leaders today, and leaves us with a call to action for leaders to see their organization through the patient's eyes. • Connect with Andrew Gallan on LinkedIn • Access The Healthcare QualityCast LinkedIn Group • Leaves Us a Rating & Review • Earn Your Lean Six Sigma for Healthcare Certification

Listen in as hosts Andrew and Jenna share a conversation with Marion Kelly, Director of Community Affairs at Mayo Clinic in Scottsdale. Marion grew up in a segregated neighborhood in Indiana, went on to study opera, and then settled in at Mayo Clinic where his talent for communication, education and politics intersect. Marion is co-founder of the Diversity Leadership Alliance (DLA), and he shares his unique experiences with systemic racism and the importance of DLA’s mission to guide leaders in the transformation of culture to build an inclusive community where each person is equally respected and empowered. Be sure to listen to the entire show; you don’t want to miss the special ending! Learn more about the organizations mentioned in the show, including DLA’s October conference: Uncomfortable Conversations: Conversations that Ignite Change. Mayo Clinic – Arizona www.mayoclinic.org/patient-visitor-guide/arizona Diversity Leadership Alliance www.diversityleadershipalliance.org/conference/ Coalition of Blacks Against Breast Cancer: cbbcaz.org/

Learn about the six-year integrated plastic surgery residency program at the Mayo Clinic in Phoenix, AZ, with Dr. Tori Aimé and Dr. Lacey Pflibsen. Recorded in August 2020.

What can patients do to advocate for themselves and the migraine community? What does advocacy look like for physicians? In this episode, Dr. Larry Newman and Dr. Starling discuss how patients can participate in self-advocacy and community advocacy as a part of their migraine journey. They also chat about physician advocacy and why it is important for patients and physicians to #MoveAgainstMigraine. Move Against Migraine host Dr. Larry Newman is Vice Chair of the American Migraine Foundation and a neurologist at NYU Langone. Dr. Amaal Starling is a neurologist and headache specialist at the Mayo Clinic Arizona and the chair of the American Headache Society’s Advocacy Committee. Additional Resources: Guide to Migraine Self-Advocacy Seeking Medical Help for Your Migraine Talking to your Doctor about Migraine

Bias in health care by Dr Poole. Dr. Kenneth Poole, Jr. was born and raised in St. Louis, MO. He earned his bachelor’s degree from Tennessee State University, his M.D. from Northwestern University, and his MBA from Washington University in St. Louis. Dr. Poole completed his residency training in internal medicine at Mercy Hospital in St. Louis and went into solo medical practice thereafter. In 2014 Dr. Poole joined the staff at Mayo Clinic Arizona, where he is Medical Director of Patient Experience, an Assistant Professor of Medicine in Mayo Clinic College of Medicine and Science, and chair of the Mayo Clinic Enterprise Health Information Coordinating Subcommittee, which oversees informatics policy. His academic interests include health economics and policy, innovation in health care delivery, and clinical informatics, and he sits on the Admissions Committee for the Mayo Clinic School of Medicine. Dr. Poole is a member of the Mayo Clinic Arizona Clinical Practice Committee and several practice-based subcommittees charged with improving care and quality throughout Mayo Clinic. He has spent time on the Mayo Clinic Arizona Space and Capital Committee and has previously chaired diversity efforts across all Mayo Clinic School of Medicine sites nationally. Dr. Poole also consults for Blue Cross Blue Shield of Arizona’s Medicare Advantage plan in a medical director capacity. Dr. Poole is a fellow of the American College of Physicians and is a Certified Physician Executive through the American Association of Physician Leadership. He sits on the board of directors for the Maricopa County Medical Society and is president of the Arizona Society of Black Physicians. He is also a member of the National Medical Association; the Arizona Medical Association; Kappa Alpha Psi Fraternity, Inc.; and Sigma Pi Phi Fraternity, Gamma Mu Boule. --Dr. Kenneth Poole, Jr. is the Medical Director of Patient Experience for Mayo Clinic Arizona. He also chairs the Mayo Clinic Enterprise Health Information Coordinating Subcommittee, which oversees informatics policy; sits on the Mayo Clinic Arizona Clinical Practice Committee; and is an Assistant Professor of Medicine in Mayo Clinic College of Medicine and Science. His academic interests include health economics and policy, innovation in health care delivery, and clinical informatics, and he sits on the Admissions Committee for the Mayo Clinic Alix School of Medicine.

Thank you for your patience!! What a whirlwind August has been. Here is my interview with the marvelous Lesley Williams, MD. She does a lot of work talking to other physicians about why weight independent health care is so important to improving health outcomes! In the episode (not in order): How Dr. Williams got involved with HAES Health Equity and health access How access and respect are due to all patients, regardless of their health goals Talking to doctors about the fear of having harmed patients unknowingly Are there fat old people? (answer: yes) Surgery on fat people Why hospitals should make sure to recognize that they have fat patients And more!   "Everyone deserves to pursue their own level of health, or lack thereof,...regardless of that pursuit, they deserve respect and access to whatever it is they need."  - Dr. Lesley Williams   About Dr. Williams: Lesley Williams, MD is a Certified Eating Disorder Specialist and board certified Family Medicine physician. She received her Doctor of Medicine degree from the University of Kentucky College of Medicine and completed her Family Medicine residency training at Mayo Clinic Arizona. She has worked exclusively with eating disorders for over 15 years in the full spectrum of treatment settings. Dr. Williams recently established Williams Wellness Medical Group, an outpatient eating disorder focused medical practice in Phoenix, AZ. She is also currently the Medical Team Lead for Banner Behavioral Health Hospital in Scottsdale, AZ. Her areas of special interest and expertise include: Health Equity and Health at Every Size Advocacy. Dr. Williams is a member of the American Academy of Family Physicians. She was recently appointed to the Academy of Eating Disorders Diversity, Equity and Inclusion Committee. Due to her hard work and dedication to the field, in 2018 Dr. Williams was named as one of the Top 80 Female Eating Disorder Leaders in the United States. lesleywilliamsmd.com www.medicalgroup.com

Guest: Mitchell R. Humphreys, M.D. (@MayoMitch)Host: Darryl S. Chutka, M.D. (@ChutkaMD)Our topic for discussion today is benign prostatic hyperplasia, or BPH. By age 60, it’s estimated that 50% of men will have some symptoms of BPH. While BPH is not a life-threatening condition, and only rarely does it result in serious health consequences, it commonly causes symptoms affecting men’s lifestyle. Our guest today is Dr. Mitchell Humphreys, chair of the Department of Urology at Mayo Clinic Arizona and Dean of the Mayo Clinic School of Continuous Professional Development.Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Teri Pipe is Arizona State University's Chief Well-Being Officer and served as the Dean of the College of Nursing and Health Innovation at Arizona State University (ASU) from 2011-2018. She also is the founding director of ASU's Center for Mindfulness, Compassion and Resilience. Before coming to ASU in 2011, Professor Pipe served as director of Nursing Research and Innovation at Mayo Clinic Arizona and was an associate professor of nursing at the Mayo Clinic’s College of Medicine. In 2014 she was selected as a Robert Wood Johnson Foundation Executive Nurse Fellow.

Josh Joseph, MD MS FAAEM, Director of Operations Research in the Department of Emergency Medicine, Beth Israel Deaconess Medical Center, and member of the AAEM Operations Management Committee, speaks with Stephen Traub MD, Chairman of the Department of Emergency Medicine, Mayo Clinic Arizona, about using a rotational patient assignment method in the Emergency Department instead of traditional methods, covering both the advantages and challenges of this approach. Intro music by SaReGaMa, Sky is the Limit, from the album Sky is the Limit, powered by JAMENDO.

Join host, Jeanne Catherine-Gray and guest author, psychologist, and burnout/resiliency specialist Joe Bailey (http://www.joebaileyandassociates.com/about.html) and hear an inspiring, extraordinary story about healing. Learn how illness is shaped by the power of the mind, and how understanding thought and consciousness can best prepare us for innate health in the face of difficult circumstances, illness, and emotional dis-ease.Bio: Joe Bailey, M.A., L.P. is an author, seminar leader, consultant to organizations, public speaker, psychotherapist and a licensed psychologist.His work has included co-founding The Minneapolis Institute of Mental Health, developing programs for health care provider wellness at the University of Minnesota and numerous hospitals including North Memorial Hospital, Minneapolis, East Lansing Health System and Mayo Clinic Arizona, treatment centers for addictions Gulf Breeze Recovery, Meridian Systems and Farnum Center, and numerous social service agencies. He is currently on the advisory board of the Innate Health Center of London.Joe has worked for over forty years as a psychotherapist, trainer, administrator, supervisor and consultant to clinics, hospitals, businesses and other government groups. He is author of six books including the best seller, Slowing Down to the Speed of Life with Dr. Richard Carlson, The Serenity Principle, Slowing Down to the Speed of Love, Fearproof Your Life: How to Thrive in a World Addicted to Fear, and his latest book that he contributed to, Creating a Marriage You’ll Love (2010). He is currently working on a new book called The Burnout Solution (Foreword by Dr. Henry Emmons, Author of The Chemistry of Joy and others). You can learn more about Joe and his work at www.joebaileyandassociates.com.

Today, human health care is in a critical position. 54% – 65% of all healthcare professionals are currently estimated to burn out due to stress. Current methods to stem the tide of burnout have focused on coping strategies and techniques that deal with stress. Unfortunately, attempting to deal with stress after it occurs increases the day to day workload. Indeed, the tools themselves must be utilized again and again for short-term satisfaction or effects.Not only are stress and burnout optional, they are preventable once we understand where our experience is coming from.See for yourself how:Previous ideas about stress have led to burnout in the helping professionsTo bounce back from adversity and prevent stressTo create a psychological immunity to perceived stressJoin Jeanne Catherine Gray as she hosts Joe Bailey in a show about rediscovering the resilient Self that is already there, whole and indestructable. Join thousands who have jump started their professional careers through gaining this simple yet profound understanding. Joe Bailey, M.A., L.P. is an author, seminar leader, consultant to organizations, public speaker, psychotherapist and a licensed psychologist. His work has included co-founding The Minneapolis Institute of Mental Health, developing programs for health care provider wellness at the University of Minnesota and numerous hospitals including North Memorial Hospital, Minneapolis, East Lansing Health System and Mayo Clinic Arizona, treatment centers for addictions—Gulf Breeze Recovery, Meridian Systems and Farnum Center, and numerous social service agencies. Joe has worked for over forty years as a psychotherapist, trainer, administrator, supervisor and consultant to clinics, hospitals, businesses and other government groups. He is author of six books including the best seller, Slowing Down to the Speed of Life with Dr. Richard Carlson, The Serenity Principle, Slowing Down to the Speed of Love, Fearproof Your Life: How to Thrive in a World Addicted to Fear, and his latest book that he contributed to, Creating a Marriage You’ll Love (2010). He is currently working on a new book called The Resilient Healer—The Epidemic of Burnout and How to Cure It (Foreword by Dr. Wyatt Decker, CEO Mayo Clinic Arizona). You can learn more about Joe and his work at www.joebaileyandassociates.com.

Have you ever wondered if you just can’t take it anymore; that the stress of helping others is just too much? Do you think stress is inevitable or is it optional? Have you ever wished you could recapture the feelings and passion you once had for helping others? Not only is stress and burnout optional, it is totally preventable once we get the paradigm of where our experience is coming from correct. The Three Principles Single Paradigm is the cure and the prevention of burnout for ourselves. Once we are enlivened by our own innate resilience, it is possible to pass it on to those we are helping. Our example is a beacon of hope for others. Join Jeanne Catherine Gray as she hosts Joe Bailey in a show about rediscovering the resilient Self that is already there, whole and indestructable. Join thousands who have jump started their professional careers through gaining this simple yet profound understanding. Joe Bailey, M.A., L.P. is an author, seminar leader, consultant to organizations, public speaker, psychotherapist and a licensed psychologist. His work has included co-founding The Minneapolis Institute of Mental Health, developing programs for health care provider wellness at the University of Minnesota and numerous hospitals including North Memorial Hospital, Minneapolis, East Lansing Health System and Mayo Clinic Arizona, treatment centers for addictions—Gulf Breeze Recovery, Meridian Systems and Farnum Center, and numerous social service agencies. Joe has worked for over forty years as a psychotherapist, trainer, administrator, supervisor and consultant to clinics, hospitals, businesses and other government groups. He is author of six books including the best seller, Slowing Down to the Speed of Life with Dr. Richard Carlson, The Serenity Principle, Slowing Down to the Speed of Love, Fearproof Your Life: How to Thrive in a World Addicted to Fear, and his latest book that he contributed to, Creating a Marriage You’ll Love (2010). He is currently working on a new book called The Resilient Healer—The Epidemic of Burnout and How to Cure It (Foreword by Dr. Wyatt Decker, CEO Mayo Clinic Arizona). You can learn more about Joe and his work at www.joebaileyandassociates.com.

In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com, interviews Alan B. Ettinger MD, MBA, Professor of Clinical Neurology, Albert Einstein College of Medicine; Epilepsy Director, NSPC Director of EEG, Huntington Hospital; Director of the Epilepsy Wellness Program, Neuroscience Institute at Winthrop University Hospital; Attending Epileptologist, Comprehensive Epilepsy Center of Long Island at St. Charles Hospital about epilepsy and ADHD in adults.